Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Immutep(LAG-3 specialist), belangrijke speler in een nieuw checkpoint voor blockbuster drugs

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Immutep(LAG-3 specialist), belangrijke speler in een nieuw checkpoint voor blockbuster drugs

639 Posts
Pagina: «« 1 ... 18 19 20 21 22 ... 32 »» | Laatste | Omlaag ↓
  2. Habsnurker 18 februari 2022 15:37
    Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

    Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce new data is scheduled to be presented at ESMO’s European Lung Cancer Congress (ELCC) 2022 which will take place in-person in Prague, Czech Republic and virtually from 30 March to 2 April 2022, Central European Summer Time (CEST).

    The new data relates to Immutep’s phase II TACTI-002 trial evaluating its lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with MSD’s KEYTRUDA® (pembrolizumab) in patients with PD-L1 unselected 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung cancer (NSCLC), known as Part B of the study. Immutep will announce the new data to the market and make the poster available on its website.

    ELCC 2022 is the annual lung cancer meeting of the European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology. It brings together multidisciplinary societies representing thoracic oncology specialists to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

    Poster presentation details
    Title: Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
    Poster display session: Friday, 1 April 2022 at 12:00 noon, CEST
    Presenter: Dr Matthew G. Krebs, The University of Manchester and The Christie NHS Foundation Trust

    About the TACTI-002 Trial
    TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of eftilagimod alpha (efti) with MSD’s KEYTRUDA® (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

    The trial is a Phase II, Simon’s two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in study centres across Australia, Europe, and the US.

    Patients participate in one of the following:

    Part A - First line Non-Small Cell Lung Cancer (NSCLC), PD-X naïve - given the promising results of the first two stages of Part A, an expansion stage with 74 additional patients was commenced in November 2020 to assist with trial design in subsequent late-stage settings
    Part B - Second line NSCLC, PD-X refractory
    Part C - Second line Head and Neck Squamous Cell Carcinoma (HNSCC), PD-X naïve

    TACTI-002 is an all-comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC.

    More information about the trial can be found on Immutep’s website or on ClinicalTrials.gov (Identifier: NCT03625323)

    About Immutep

    Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

    Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

    Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
  3. Maisha marefu 25 februari 2022 10:36
    Immutep Appoints Lucy Turnbull as Non-Executive Director
    SYDNEY, AUSTRALIA – 25 February 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or
    “the Company”) is pleased to announce the appointment of Lucy Turnbull AO as Non-executive Director
    of Immutep, effective immediately.
    Ms Turnbull rejoins Immutep’s Board having previously served as its Chairman from October 2010 to
    November 2017, stepping down from the role only due to her elevated professional and personal
    commitments at the time. Since then Ms Turnbull has remained close to the Company and following the
    recent tragic passing of Grant Chamberlain, has agreed to replace him as Non-Executive Director.
    Ms Turnbull is a distinguished Australian businesswoman, philanthropist and former local government
    politician. With a background in commercial law and investment banking, she was the first female Lord
    Mayor of the City of Sydney from 2003 to 2004 and has served on the boards of the NSW Cancer Institute,
    the Sydney Children's Hospital Foundation, the Sydney Cancer Centre and the Sydney Festival.
    In 2011, Ms Turnbull was appointed an Officer of the Order of Australia for her service to the community,
    local government and business, including through her philanthropic contributions and fundraising for a
    range of medical, social welfare, educational, youth and cultural organisations. From 2015 to 2020 she
    served as the inaugural Chief Commissioner of the Greater Sydney Commission, a NSW state government
    body focused on delivering strategic planning for the whole of metropolitan Sydney.
    “It is a pleasure to welcome Lucy back to the Immutep Board,” said Chairman Dr Russell Howard. “The
    Company is at an incredibly exciting juncture given its clinical results in multiple cancer indications and
    growing global recognition as the leader in LAG-3 immuno-therapy. With Lucy’s business acumen, passion
    for innovative cancer treatments and extensive knowledge of the Company, her contribution will be wide
    reaching and most valued.”
    “As a shareholder and longstanding supporter, I have followed Immutep closely in the intervening years
    and it has been marvellous to see so much achieved by the talented team who I am delighted to be
    working with again. Immutep is an exceptionally promising biotech with innovative technology that could
    deliver a meaningful benefit to many cancer patient groups around the world,” said Lucy Turnbull.
    About Immutep
    Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related
    immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated
    to leveraging its technology and expertise to bring innovative treatment options to market for patients
    and to maximise value to shareholders.
    Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion
    protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer
    and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
    Additional LAG-3 products, including antibodies for immune response modulation, are being developed
    by Immutep’s large pharmaceutical partners.
  8. forum rang 6 Goudmijn64 10 maart 2022 19:12
    quote:

    Goudmijn64 schreef op 9 maart 2022 23:05:

    Eindelijk weer eens een mooi bericht wat de koers structureel hoger zal zetten. Op naar de 5 usd en hoger.
    helaas iets te optimistisch geweest met mijn post van gisteren.
    de wens is de vader van de gedachte.
    Ik blijf rustig long, want we worden echt een keer beloond met een pb wat de markt zal belonen met een structurele verhoging van de koers.
  9. De kakelende kip 14 maart 2022 08:01
    quote:

    Goudmijn64 schreef op 10 maart 2022 19:12:

    [...]

    helaas iets te optimistisch geweest met mijn post van gisteren.
    de wens is de vader van de gedachte.
    Ik blijf rustig long, want we worden echt een keer beloond met een pb wat de markt zal belonen met een structurele verhoging van de koers.
    de hele biotech ligt op z'n gat en we gaan een recessie in, wordt een hele moeilijke markt.
  11. Dag Trader 18 maart 2022 17:06
    spanning wordt opgebouwd... morgen d-day voor LAG-3 Bristol Myers... PDUFA date....

    news.bms.com/news/details/2021/U.S.-F...

    gaat dit de LAG-3 nu eindelijk ook valideren in koersen??

    ondertussen.....
    Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

    www.immutep.com/files/content/investo...

    Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022

    www.immutep.com/files/content/investo...

  13. M c M 20 maart 2022 04:34
    quote:

    Ikkedike schreef op 19 maart 2022 07:33:

    Het feest mag beginnen !
    news.bms.com/news/details/2022/U.S.-F...
    Nu kan het inderdaad écht losgaan!
    Helaas staan we nu pas weer rond m'n laatste aankoop, nu zijn er de laatste tijd wat dingetjes gebeurd die weinigen vooraf ingeschat hadden.
    Neem aan dat dit een flinke impuls gaat geven, aan de andere kant bezit ik ook een aandeel dat na hun Hep-B FDA goedkeuring gewoon 60% lager gezet werd.

    Het timen van de markt wordt me steeds moeilijker. Zit ook nog eens tot vrijdag zonder telefoon dus ik geef maar een hele hoge verkooporder mee en we zien het eind van de week wel weer.

    Succes allen!
639 Posts
Pagina: «« 1 ... 18 19 20 21 22 ... 32 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,85 -0,52%
EUR/USD 1,0651 +0,07%
FTSE 100 7.831,47 -0,58%
Germany40^ 17.717,40 -0,67%
Gold spot 2.380,94 +0,07%
NY-Nasdaq Composite 15.601,50 -0,52%

Stijgers

WDP
+3,76%
EBUSCO...
+3,46%
Heineken
+1,45%
Pharming
+1,21%
NSI
+0,91%

Dalers

AMG Cr...
-2,69%
TomTom
-2,42%
RENEWI
-2,06%
Aegon
-2,01%
KPN
-1,89%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!